Guggenheim Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $42
Portfolio Pulse from richadhand@benzinga.com
Guggenheim analyst Michael Schmidt maintains a Buy rating on Syndax Pharmaceuticals (NASDAQ:SNDX) and raises the price target from $40 to $42.
July 25, 2023 | 12:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Guggenheim maintains a Buy rating on Syndax Pharmaceuticals and raises the price target from $40 to $42.
The news of Guggenheim maintaining a Buy rating and raising the price target for Syndax Pharmaceuticals is likely to have a positive impact on the company's stock in the short term. This is because it signals the analyst's confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100